Pharmacokinetics, Pharmacodynamics, and Safety of Landiolol Hydrochloride in Healthy Chinese Subjects

Abstract

Objective:

Landiolol is an ultra-short-acting β-blocker that appears to be more cardioselective and less toxic than esmolol. The main objective of this study was to investigate the pharmacokinetics, pharmacodynamics, and safety of landiolol hydrochloride in healthy Chinese volunteers.

Methods:

We set 2-dose regimen (L and H groups) [L (low): 0.125 mg/kg/min (1 min) loading→0.02 mg/kg/min (20 min) continuous, H (high): 0.25 mg/kg/min (1 min) loading→0.04 mg/kg/min (20 min) continuous]. 20 healthy subjects of either sex were allocated randomly to the L and H groups (n=10, and 10). Blood samples were collected over 1 h after continuous infusion and were determined using a validated liquid chromatography/mass spectrometry (LC/MS/MS) assay. The safety of landiolol hydrochloride was assessed by adverse events recording, 12-lead ECG findings, physical examination, laboratory testing, and vital signs.

Results:

The main pharmacokinetic parameters of landiolol hydrochloride in healthy Chinese subjects were as follows: doses of 2 groups (L and H); C_max of 400±110 and 731±246 ng/mL; C_21min of 327±109 and 508±141 ng/mL; T_max of 10.1±6.5 and 6.2±5.7 min; t_1/2 of 4.7±1.6 and 6.5±1.7 min. Landiolol hydrochloride was safe. There were no adverse events in any subject. The heart rates and blood pressures of subjects administered landiolol hydrochloride decreased, but no clinically significant changes were observed.

Conclusion:

The concentration of landiolol hydrochloride rapidly reached steady state levels, and rapidly dissipated after completion of administration. Landiolol hydrochloride appears to have rapid onset and short action.

Key words

landiolol hydrochloride - ultra short-acting β1-blocker - pharmacokinetics - pharmacodynamics - safety

• References

• 1 Andrews TC, Reimold SC, Berlin JA et al. Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. Circulation 1991; 84: 236-244
• 2 Kowey PR, Taylor JE, Rials SJ et al. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol 1992; 69: 963-965
• 3 Crystal E, Connolly SJ, Sleik K et al. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002; 106: 75-80
• 4 Murakami M, Furuie H, Matsuguma K et al. Pharmacokinetics and Pharmacodynamics of landiolol hydrochloride, an ultra short-acting beta1-selective blocker, in a dose escalation regimen in healthy male Volunteers. Drug Metab Pharmacokinet 2005; 20: 337-344
• 5 Iguchi S, Iwamura H, Nishizaki M et al. Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101. Chem Pharm Bull (Tokyo) 1992; 40: 1462-1469
• 6 Atarashi H, Kuruma A, Ino T et al. ONO-1101: a new ultra-short acting beta-adrenergic blocker: initial study of efficacy, safety and pharmacokinetics. Cardiovasc Drugs Ther 1993; 7: 444
• 7 Tsunekawa K, Imawaka H, Yamamoto K et al. Studies on the metabolic fate of ultra short acting β₁ blocker ONO-1101 (3): metabolism and protein binding. Xenobio Metabol and Dispos 1997; 12: 31-41
• 8 Nakashima M, Kanamaru M. Phase I study of ONO-1101, a new ultra short acting β₁-blocking agent in healthy volunteers. Rinsho Iyaku 2000; 16: 1531-1556
• 9 Ommen SR, Odell JA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery. N Engl J Med 1997; 336: 1429-1434